{"slideshow_credits": null, "snippet": "Pershing Square\u2019s accumulation of shares in Allergan before a takeover bid was disclosed raises the question of how far the prohibition on insider trading ought to extend, Peter J. Henning writes in the White Collar Watch column.", "abstract": "Pershing Square\u2019s accumulation of shares in Allergan before a takeover bid was disclosed raises the question of how far the prohibition on insider trading ought to extend, Peter J. Henning writes in the White Collar Watch column.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"lastname": "HENNING", "rank": 1, "firstname": "Peter", "role": "reported", "organization": "", "middlename": "J."}], "original": "By PETER J. HENNING"}, "web_url": "http://dealbook.nytimes.com/2014/08/18/fight-for-maker-of-botox-tests-scope-of-insider-trading-laws/", "lead_paragraph": null, "headline": {"main": "Fight for Maker of Botox Tests Scope of Insider Trading Laws", "kicker": "DealBook"}, "_id": "53f22aec38f0d847437df6df", "word_count": "1159", "multimedia": [{"height": 126, "url": "images/2014/08/18/business/dealbook/dbpix-ackman/dbpix-ackman-thumbWide-v3.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/08/18/business/dealbook/dbpix-ackman/dbpix-ackman-thumbWide-v3.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2014/08/18/business/dealbook/dbpix-ackman/dbpix-ackman-articleLarge-v3.jpg", "legacy": {"xlarge": "images/2014/08/18/business/dealbook/dbpix-ackman/dbpix-ackman-articleLarge-v3.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/08/18/business/dealbook/dbpix-ackman/dbpix-ackman-thumbStandard-v3.jpg", "legacy": {"thumbnail": "images/2014/08/18/business/dealbook/dbpix-ackman/dbpix-ackman-thumbStandard-v3.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-08-18T12:32:19Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Allergan Inc", "rank": "1"}, {"name": "organizations", "value": "Pershing Square Capital Management", "rank": "2"}, {"name": "organizations", "value": "Securities and Exchange Commission", "rank": "3"}, {"name": "organizations", "value": "Valeant Pharmaceuticals International Inc", "rank": "4"}, {"name": "subject", "value": "Insider Trading", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}, {"name": "subject", "value": "Regulation and Deregulation of Industry", "rank": "3"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}